As noted earlier, Wedbush downgraded Endocyte to Neutral from Outperform. Analyst David Nierengarten downgraded the stock after the company reported that the level of activity observed in trials did not support further development of its EC1456 or its EC1169 in taxane-naive CRPC. The company will only develop EC1169 in the taxanes-exposed CRPC population going forward and will discontinue EC1456, the analyst reported. He removed all sales from both drugs from his model ,citing uncertain initial results of 1169 in the taxane-exposed population. Target to $2 from $8.